mTOR pp 279-293 | Cite as

Expanding Human T Regulatory Cells with the mTOR-Inhibitor Rapamycin

  • Manuela Battaglia
  • Angela Stabilini
  • Eleonora Tresoldi
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 821)

Abstract

CD4+CD25+FOXP3+ T regulatory (Treg) cells are pivotal for the induction and maintenance of peripheral tolerance in both mice and humans. The possibility to use Treg cells for the treatment of T-cell-mediated diseases has recently gained increasing momentum. However, given the limited amount of circulating FOXP3+ Treg cells, efficient methods for their ex vivo expansion are highly desirable. Rapamycin allows for in vitro expansion of murine and human FOXP3+ Treg cells, which maintain their regulatory phenotype and suppressive capacity. Here, we describe in detail the powerful methods for enriching human FOXP3+ Treg cells starting from unfractionated CD4+ T cells or for expanding CD25+-enriched Treg cells in the presence of rapamycin.

Key words

Immunological tolerance Regulatory T cells Rapamycin 

Notes

Acknowledgments

This work was supported by the Italian Telethon Foundation and the Juvenile Diabetes Research Foundation (GJT04014). This study was also supported in part by research funding from BD Biosciences.

References

  1. 1.
    Curotto de Lafaille, M. A., and J. J. Lafaille (2009) Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30, 626–635.PubMedCrossRefGoogle Scholar
  2. 2.
    Wing, K., and S. Sakaguchi (2010) Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11, 7–13.PubMedCrossRefGoogle Scholar
  3. 3.
    Malek, T. R., and I. Castro (2010) Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity. Immunity 33, 153–165.PubMedCrossRefGoogle Scholar
  4. 4.
    Roncarolo, M. G., and M. Battaglia (2007) Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 7, 585–598.PubMedCrossRefGoogle Scholar
  5. 5.
    Battaglia, M., A. Stabilini, and M. G. Roncarolo (2005) Rapamycin selectively expands CD4  +  CD25  +  FoxP3+ regulatory T cells. Blood 105, 4743–4748.PubMedCrossRefGoogle Scholar
  6. 6.
    Battaglia, M., A. Stabilini, B. Migliavacca, J. Horejs-Hoeck, T. Kaupper, and M. G. Roncarolo (2006) Rapamycin promotes expansion of functional CD4  +  CD25  +  FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 177, 8338–8347.PubMedGoogle Scholar
  7. 7.
    Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. Basu S, Golovina T, Mikheeva T, June CH, Riley JL. J Immunol. 2008 May 1;180(9):5794–8.PubMedGoogle Scholar
  8. 8.
    Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells. Tresoldi E, Dell’albani I, Stabilini A, Jofra T, Valle A, Gagliani N, Bondanza A, Roncarolo MG, Battaglia M. Haematologica. 2011 Sep; 96(9):1357–65.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC  2012

Authors and Affiliations

  • Manuela Battaglia
    • 1
    • 2
  • Angela Stabilini
    • 2
  • Eleonora Tresoldi
    • 1
  1. 1.San Raffaele Telethon Institute for Gene TherapyMilanItaly
  2. 2.San Raffaele Diabetes Research InstituteMilanItaly

Personalised recommendations